🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

Australia to review EU findings on AstraZeneca vaccine and blood clots

Published 08/04/2021, 09:37 am
Updated 08/04/2021, 09:42 am
© Reuters.
CSL
-
AZN
-
AZN
-

By Renju Jose

SYDNEY, April 8 (Reuters) - Australia on Thursday ordered an urgent inquiry into findings from Europe's drug regulator of a possible link between AstraZeneca (NASDAQ:AZN)'s AZN.L COVID-19 vaccine and blood clotting.

The European Medicines Agency on Wednesday said it found rare cases of blood clots among some adult vaccine recipients, although it said the vaccine's advantages still outweighed the risks. government has asked (the immunisation advisory group) and (medicines regulator) to immediately consider and advise on the latest vaccination findings out of Europe and the UK," a health ministry spokeswoman said in an emailed statement.

Australian regulators have already been working with their international counterparts to consider the latest findings, the spokeswoman said.

The latest findings from the European regulator prompted Britain to recommend that people under 30 should get an alternative coronavirus vaccine, while Italy suggested AstraZeneca shots should only be used on those over 60. two recommendations will be brought to the table today and looked at in the Australian context," Australia Chief Medical Officer Paul Kelly told the Australian Broadcasting Corp.

But Kelly said the unusual blood clots among some vaccine recipients were "extremely rare", and that the AstraZeneca doses were safe and effective for most people.

The EU decision could further complicate Australia's immunisation programme, which is more than 80% behind its original schedule, as it relies heavily on the AstraZeneca shots to vaccinate its near 26 million population.

Australian authorities had pledged to administer at least 4 million first doses by the end of March, but could only deliver 670,000. The government blamed supply issues from Europe for the delay.

It is looking to ramp up the immunisation programme from locally produced AstraZeneca vaccines, with 50 million doses set to be produced in Australia by CSL Ltd CSL.AX .

Australia began vaccinations much later than some other countries due to low COVID-19 case numbers, recording just under 29,400 infections and 909 deaths since the pandemic began.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.